MYOV Myovant Sciences Ltd.

8.75-0.03 (-0.34%)
IEX real time price: 12:29:37 PM

Quote

Previous Close
$8.78
Day Range
$8.55-$8.87
52 Week Range
$8.33-$27.45
Volume
26,418
Avg Volume
216,631
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$631.73M
Enterprise Value (EV)
$577.21M
PE Ratio
-
EV/EBITDA
-2.18
Price/Sales
-
Price/Book
146.26
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-$438.00K
EBITDA
-$264.39M
EPS, ttm
-$4.08
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
8/13/2019 (26 days)
Debt to Equity
2,293%
Debt
$101.55M
Cash
$156.07M
Net Debt
-

Performance

Beta
0.80
200 Day Moving Avg
$17.81
50 Day Moving Avg
$10.73
52 Week Change
-56.60%
YTD Change
-48.48%
1 Month Change
-5.29%
3 Month Change
-52.23%
6 Month Change
-52.00%
1 Year Change
-56.60%
2 Year Change
52.01%
5 Year Change
39.74%

Share Count

Shares Outstanding
72.2M
Float
-
Restricted Shares
72.2M
Restricted Shares, %
100.00%

Myovant Sciences Ltd. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Lynn Seely

Website: http://www.myovant.com

Description: Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Employees: 167